English
SpanishTrusted Resources: News & Meetings
Latest announcements and gatherings
Immunovant Announces Two New Development Programs for Batoclimab
Immunovant, Inc., a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced plans to develop batoclimab in Chronic Inflammatory Demyelinating Polyneuropathy and Graves’ Disease. “We are excited to announce the addition of two new target indications for batoclimab, one of which will be a pivotal program, confirming our confidence in the broad development opportunity for batoclimab,” said Pete Salzmann, M.D., Chief Executive Officer of Immunovant.
“With regard to Graves’ Disease, current treatments leave a meaningful proportion of patients unable to achieve normal thyroid hormone function and many remain symptomatic even when on current therapies”, said Dr Salzmann. “As a classic autoantibody condition, the straightforward biology of Graves’ Disease, from pathogenic autoantibody to altered hormones, provides solid scientific rationale for the indication, supported by anecdotal data from our Thyroid Eye Disease Phase 2b trial.
myBinderRelated Content
-
Michael Campbell, MDMichael Campbell is a fellowship-trained...
-
Thyroid Disorders and OsteoporosisWhat is Osteoporosis? Osteoporosis - li...
-
Patients’ Perceptions and Views of Surgery and Radioiodine Ablation in the Definitive Management of GravesR...Background: Patients' perceptions and p...
-
Predictive Score for the Development or Progression of Graves’ Orbitopathy in Patients With Newly Diagnosed Gr...Objective: To construct a predictive sc...
-
David Schneider, MD, MS, FACSDr. Schneider is certified by the Americ...
-
Jacqueline T. Kung, MDJacqueline T. Kung is the Director of Th...
-
Beth Israel Deaconess Medical Center – Thyroid CenterThe Thyroid Center, the Division of Endo...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Brought to you by
Supported through an independent
educational grant by
